Nebenwirkungen · Aprovel
Aprovel 300 mg tablets. · Abschnitt 4.8 · PDF-Seite 33
HOS-087045 · Präparat HOS-083419
In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:05:00Z · SHA-256 9a7fe6a40dc5304cc03e5692e73b5a8b0895fbc3156dd4f3a748f38e97336ae6 · Passage 0ebd24f97b1d13a677c8c529788a7269ed79ef1c415b75d05f915761a4baf316 · Zeichen 0–474 im Abschnitt